Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

H. Cody Meissner(Creighton University), William J. Rodriguez(Creighton University), Charles Welliver(Women & Children's Hospital of Buffalo), S A Chartrand(Creighton University), Barbara Law(Creighton University), Leonard E. Weisman(Creighton University), Henry L. Dorkin(Boston Children's Hospital)
The Pediatric Infectious Disease Journal
March 1, 1999
10.1097/00006454-199903000-00004
Cited by 129

Related Papers

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation
|Thorax|2011|501
Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis
|New England Journal of Medicine|1993|458
Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs
|Human Molecular Genetics|1993|414
Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial
|Human Gene Therapy|2007|275
Airway area by acoustic reflections measured at the mouth
|Journal of Applied Physiology|1980|250